Economic impact of genomic diagnostics for intermediate‐risk acute myeloid leukaemia

Acute Myeloid Leukaemia (AML) is a rare but serious group of diseases that require critical decision‐making for curative treatment. Over the past decade, scientific discovery has revealed dozens of prognostic gene mutations for AML while sequencing costs have plummeted. In this study, we compared th...

Descripción completa

Detalles Bibliográficos
Autores principales: Cressman, Sonya, Karsan, Aly, Hogge, Donna E., McPherson, Emily, Bolbocean, Corneliu, Regier, Dean A., Peacock, Stuart J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Haematological Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021117/
https://www.ncbi.nlm.nih.gov/pubmed/27098559
http://dx.doi.org/10.1111/bjh.14076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021117/
https://www.ncbi.nlm.nih.gov/pubmed/27098559
http://dx.doi.org/10.1111/bjh.14076

Ejemplares similares